Business Strategy

Xention is capitalizing on the under-exploitation of ion channel drug targets. To achieve this, we have developed an integrated approach to ion channel drug discovery comprising numerous critical components proprietary to the Company. We believe that our unique asset base and expertise will allow us to exploit this very significant opportunity.

We plan to capitalize on our expertise by progressing our key internal programs to clinical proof-of-concept at which point we will seek development partnerships with third parties with a track record in the respective therapeutic area/s.